Hematopoietic stem cells (HSCs) quiescently reside in bone marrow niches and have the capacity to self-renew or differentiate to form all of the blood cells throughout the lifespan of an animal [1] [2] [3] . Allogeneic HSC transplantation is a life-saving treatment for malignant and nonmalignant disorders 4, 5 . HSCs isolated from umbilical cord blood (CB) are used for hematopoietic cell transplantation (HCT) [6] [7] [8] [9] [10] [11] , but due to the limited numbers of HSCs in single units of umbilical CB, a number of methods have been proposed for ex vivo expansion of human HSCs 7, 8, 12 . We show here that antagonism of peroxisome proliferator-activated receptor (PPAR)-g promotes ex vivo expansion of phenotypically and functionally defined subsets of human CB HSCs and hematopoietic progenitor cells (HSPCs). PPAR-g antagonism in CB HSPCs strongly downregulated expression of several differentiation-associated genes, as well as fructose-bisphosphatase 1 (FBP1; which encodes a negative regulator of glycolysis), and enhanced glycolysis without compromising mitochondrial metabolism. The expansion of CB HSPCs by PPAR-g antagonism was completely suppressed by removal of glucose or inhibition of glycolysis. Moreover, knockdown of FBP1 expression promoted glycolysis and ex vivo expansion of long-term repopulating CB HSPCs, whereas overexpression of FBP1 suppressed the expansion of CB HSPCs that was induced by PPAR-g antagonism. Our study suggests the possibility for a new and simple means for metabolic reprogramming of CB HSPCs to improve the efficacy of HCT.
The limited numbers of HSCs that are present in single units of CB are still an obstacle for more widespread clinical use of CB for HCT 7, 8 . To overcome this limitation, a number of efforts to expand HSCs in CB have been made [10] [11] [12] [13] [14] [15] [16] . However, there is need for other means to improve the clinical efficacy of HCT through a better mechanistic understanding of the regulation and ex vivo expansion of CB HSPCs.
We first performed a screen to search for small-molecule compounds that could promote ex vivo expansion of a rigorously defined population of HSCs (Lin − CD34 + CD38 − CD45RA − CD49f + CD90 + , as characterized using flow cytometry) 17 that were isolated from fresh human CB, as tested in RPMI-1640 medium containing 10% fetal bovine serum (FBS) and cytokines (stem cell factor (SCF), thrombopoietin (TPO) and Fms-like tyrosine kinase 3 ligand (FL)). From a library of nuclear hormone receptor ligands comprising 74 compounds 18 , we found that treatment with a PPAR-γ antagonist, GW9662, significantly enhanced cytokine-stimulated (SCF, TPO and FL) ex vivo expansion of this population of human CB HSCs at days 4 and 7 of culture ( Fig. 1a-c, Supplementary Figs. 1a ,b and 2a, and Supplementary Table 1 ). GW9662 treatment also enhanced expansion of CB CD34 + CD38 − cells and multipotential progenitors (MPPs; Lin − CD34 + CD38 − CD45RA − CD49f − CD90 − ) ( Supplementary  Fig. 2b,c) . Another PPAR-γ antagonist, T0070907, also enhanced expansion of human CB HSCs. Modulation of the activity of PPAR-α or PPAR-δ, two other subtypes of the PPAR nuclear hormone receptor family, had no effect on ex vivo expansion of CB HSCs (Supplementary Fig. 2d ).
Hematopoietic progenitor cells (HPCs) also contribute to steadystate hematopoiesis during most of adulthood 19 . GW9662 treatment significantly increased the numbers of CB colony-forming unit (CFU) granulocyte-macrophage (GM) and granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) progenitors after 4 d of ex vivo culture (Fig. 1d) , demonstrating that antagonism of PPAR-γ also promoted ex vivo expansion of functionally recognizable HPCs.
PPARG (which encodes PPAR-γ) was highly expressed in CB HSCs and MPPs ( Supplementary Fig. 2e,f) . Notably, knockdown of PPARG substantially enhanced ex vivo expansion of CB HSCs ( Supplementary Fig. 2g,h ), suggesting that PPAR-γ signaling might function as a negative regulator of CB HSC self-renewal.
The effect of GW9662 on expansion of human CB HSCs was reversible ( Supplementary Fig. 3a) , and treatment with GW9662 in the absence of cytokines had no mitogenic activity ( Supplementary  Fig. 3b) . The rates of cell division and apoptosis were unchanged by GW9662 treatment (Supplementary Fig. 3c,d) . In contrast to its effects on human CB HSCs, GW9662 did not promote ex vivo expansion of phenotypically defined mouse HSCs (CD150 + CD48 − LSK) ( Supplementary Fig. 4a,b) , suggesting that PPAR-γ signaling might not regulate the expansion of mouse HSCs.
To assess whether the ex vivo expansion of functional human CB HSPCs was enhanced by PPAR-γ antagonism, we transplanted the progeny of 30,000 CB CD34 + cells that had been cultured with a vehicle control or with GW9662 for 4 d into sublethally irradiated immunodeficient NOD-SCID IL-2rγ null (NSG) mice. There was significantly more engraftment of CB CD34 + cells that had been cultured with GW9662 than those cultured with vehicle in both the bone marrow (BM) and peripheral blood (PB) of the recipient mice (Fig. 2a,b) . Treatment with GW9662 also increased the percentages of both myeloid and lymphoid lineage cells in the BM of primary recipients (Fig. 2c-e and Supplementary Fig. 5a-c) , demonstrating that CB CD34 + cells cultured with GW9662 contain functionally engrafting HSCs. Next we tested the effect of PPARG knockdown by transplanting CB CD34 + cells that had been transfected with a control short hairpin RNA (shRNA) or a PPARG-specific shRNA into NSG recipient mice. As compared to cells transfected with the control shRNA, transplantation of CB CD34 + cells that had been transfected with a PPARG-specific shRNA enhanced both myeloid and lymphoid chimerism in the BM of recipients (Supplementary Fig. 5d ). We confirmed the long-term capability of GW9662-treated CB CD34 + cells to be reconstituted and undergo self-renewal; 4 months after transplantation of BM from primary recipients into sublethally irradiated secondary NSG recipient mice, myeloid and lymphoid chimerism in both the PB and BM were enhanced in the GW9662 treatment group, as compared to that in the vehicle treatment group ( Fig. 2f and Supplementary Fig. 6a ). We performed two independent limiting-dilution experiments to hCD45 APC-A 0.32% 2.81% 8.37%
Negative control 10 replicates from two independent experiments). Symbols represent XX, and data are depicted as mean ± s.d. **P < 0.01 and ***P < 0.001 by two-tailed Student's t-test. (c,d) Representative western blot analysis (c) and quantification (n = 3 independent experiments) (d) of FBP1 expression in vehicle-or GW9662-treated human CB CD34 + cells. Actin was used as a loading control. **P = 0.004 by two-tailed Student's t-test. The uncropped blot is shown in Supplementary Figure 13 . (e,f) Representative histogram (e) and quantification (n = 3 independent experiments) (f) of FBP1 expression in vehicleor GW9662-treated human CB HSCs, as analyzed by FACS. ***P = 0.0002 by two-tailed Student's t-test. MFI, mean fluorescence intensity. (g) ECAR measurements in purified CB CD34 + cells following a 4-d culture with vehicle or GW9662. Data pooled from three independent experiments are shown as mean ± s.d. **P = 0.0018 and ***P = 0.0008 by two-tailed Student's t-test. Oligomycin is an inhibitor of ATP synthase. 2-DG, 2-deoxyglucose. (h) Relative glucose uptake in vehicle-or GW9662-treated CB CD34 + cells. Glucose uptake was determined by FACS, on the basis of the MFI values of the incorporated fluorescent glucose analog 2-NBDG (n = 3 independent experiments). The value of vehicle group was set as "1". Data are shown as mean ± s.d. ***P = 0.00016 by two-tailed Student's t-test. (i) Relative levels of lactate secreted by vehicle-or GW9662-treated CB CD34 + cells (n = 3 independent experiments). Data are shown as mean ± s.d. **P = 0.0049 by two-tailed Student's t-test. (j) OCR measurements in purified CB CD34 + cells following a 4-d culture with vehicle or GW9662. Carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) is a potent mitochondrial oxidative phosphorylation uncoupler; rotenone is an inhibitor of mitochondrial respiratory chain complex I. Representative data from three independent experiments are shown as mean ± s.d. (k) CB HSC ex vivo expansion after treatment with vehicle or GW9662 in complete medium (with glucose) or in glucose-free medium, as determined on day 4 of culture. Data pooled from three independent experiments are shown as box-and-whisker plots (the lines indicate median values, the whiskers indicate minimum and maximum values, and the boxes indicate interquartile range) (n = 9 cultures per group). ***P < 0.001 by one-way ANOVA. (l) CB HSC expansion in the presence of vehicle, GW9662 (1 µM), 2-DG (1 mM) or GW9662 (1 µM) + 2-DG (1 mM), as determined at day 4 of culture. Data pooled from two independent experiments are shown as box-and-whisker plots (the lines indicate median values, the whiskers indicate minimum and maximum values, the boxes indicate interquartile range) (n = 6 cultures per group). **P = 0.002 and ***P < 0.001 by one-way ANOVA.
calculate the number of severe combined immunodeficiency (SCID)-repopulating cells (SRCs) 1 , a measure of the number of functionally engrafting human HSCs. Cells that were cultured in the presence of cytokines (SCF, FL, TPO) did not demonstrate enhanced SRC numbers as compared to that for uncultured CD34 + cells; however, the SRC frequency of GW9662-cultured CB CD34 + cells was fourfold higher than that of day 0 uncultured CD34 + cells, and it was fivefold higher than that of vehicle-treated CD34 + cells that had been cultured in the presence of cytokines (Fig. 2g,h, Supplementary  Fig. 6b,c and Supplementary Tables 2-5 ). These data demonstrated that antagonism of PPAR-γ in CB CD34 + cells leads to increased numbers of long-term engrafting and self-renewing HSCs.
To gain mechanistic insight into how PPAR-γ antagonism promotes ex vivo expansion of human CB HSPCs, we performed RNA sequencing (RNA-seq) analysis. Treatment of CB CD34 + cells with GW9662 resulted in downregulation of a number of differentiation-associated genes [20] [21] [22] [23] [24] [25] -including CD38, CD1D, HIC1, FAM20C, DUSP4, DHRS3 and ALDH1A2 (Fig. 3a,b and Supplementary Fig. 7a,b) -suggesting that PPAR-γ antagonism may maintain the 'stemness' of CB CD34 + cells, at least in part by preventing differentiation. We also observed that expression of FBP1, which encodes a negative regulator of glycolytic flux 26, 27 , was significantly downregulated in GW9662-treated CB CD34 + cells ( Fig. 3a and Supplementary Fig. 7a,b) . We confirmed that FBP1 expression was decreased in GW9662-treated CB CD34 + cells using real-time quantitative PCR, western blot analysis and flow cytometry analysis (Fig. 3b-f) . GW9662 treatment did not significantly change the expression of other genes involved in glycolysis in HSCs (PKM2 and LDHA) 28 (Supplementary Fig. 7c ), suggesting the specific targeting of PPAR-γ antagonism on FBP1 expression. Because PPAR-δ-targeted fatty acid oxidation (FAO) regulates mouse HSC maintenance 29 , we also evaluated the expression of genes involved in FAO. However, FAO-associated gene expression (CPT1A, ANGPTL4 and ACOX1) was not increased after PPAR-γ antagonism in CB HSPCs (Supplementary Fig. 7d) . Consistent with the data that showed no significant effect of GW9662 treatment on expansion of mouse BM HSPCs, differentiation-associated genes (Cd38, Cd1D, Hic1, Fam20c, Dusp4, Dhrs3 and Aldh1A2) and Fbp1 in mouse BM HSPCs were not downregulated by PPAR-γ antagonism (Supplementary Fig. 7e ). We then wondered whether PPAR-γ antagonism would promote glycolysis. By directly measuring the extracellular acidification rate (ECAR) using a Seahorse XF extracellular flux instrument, we observed that GW9662-treated CB CD34 + cells had significantly higher glycolytic activity than vehicle-treated cells (Fig. 3g) . Moreover, GW9662 treatment of CB CD34 + cells promoted glucose uptake and lactate production (Fig. 3h,i) . In contrast, the extracellular oxygen consumption rate (OCR) was not affected by GW9662 treatment (Fig. 3j) , suggesting that PPAR-γ antagonism enhances glycolysis without compromising mitochondrial metabolism. Ex vivo expansion of CB HSCs by GW9662 treatment was blocked by glucose depletion (Fig. 3k) , as well as by administration of 2-deoxy-d-glucose (2-DG) (Fig. 3l) , a well characterized inhibitor of glycolysis 30 . These data demonstrate that HSPC expansion by PPAR-γ antagonism depends on its enhancement of glucose metabolism.
To test whether loss of FBP1 was sufficient to promote ex vivo expansion of human CB phenotypic HSCs (pHSCs), we treated CB CD34 + cells with MB05032, a specific inhibitor of FBP1 (ref. 31) , or transfected cells with shRNA targeting FBP1. Relative to vehicle treatment, treatment with MB05032 significantly promoted expansion of human CB pHSCs and CD34 + CD38 − cells (Fig. 4a and Supplementary Figs. 8a and 9a, and Supplementary Table 6); this expansion was dependent on continuous treatment with MB05032 (Supplementary Fig. 9b) . Knockdown of FBP1 also promoted expansion of CB pHSCs ( Fig. 4b  and Supplementary Fig. 9c ). Although overexpression of FBP1 had no effect on expansion of CB pHSCs, it completely blocked the expansion of CB pHSCs that was induced by PPAR-γ antagonism (Fig. 4c) . Consistent with the concept that repression of FBP1 expression has a key role in the expansion of human CB pHSCs by PPAR-γ antagonism, FBP1 overexpression significantly suppressed the increase in SRCs of GW9662-treated CD34 + cells (Fig. 4d,e and Supplementary  Table 7 ). MB05032 treatment also increased the numbers of CFU-GM and CFU-GEMM progenitors (Supplementary Fig. 9d ). MB05032 treatment did not further enhance the effects of GW9662 on the expansion of CB pHSCs, as well as of CFU-GM and CFU-GEMM progenitors (Supplementary Fig. 9e,f) , indicating that PPAR-γ and FBP1 likely function in the same pathway.
Next we performed a limiting-dilution engraftment assay to determine the functional HSC frequency of CB CD34 + cells that had been cultured with cytokines and treated with either a vehicle control or MB05032. MB05032-treated CB cells demonstrated significantly increased engraftment in primary NSG recipients 4 months after transplantation as compared to that in the vehicle control group (Fig. 4f and Supplementary Fig. 9g,h) , with increased human myeloid, B cell and T cell chimerism ( Fig. 4f and Supplementary  Fig. 9i-k) . MB05032 treatment also substantially enhanced myeloid and lymphoid chimerism in secondary NSG mouse recipients (Supplementary Fig. 10a ), suggesting that CB HSCs expanded by inhibition of FBP1 have long-term reconstituting capacity and selfrenewal activity. Poisson distribution analysis revealed an SRC frequency of 1:4,703 in uncultured day 0 CB CD34 + cells, 1:5,612 in vehicle-treated CB CD34 + cells and 1:1,328 in MB05032-treated CB CD34 + cells (Fig. 4g,h and Supplementary Tables 4 and 5) , suggesting the presence of 212 SRCs, 178 SRCs and 753 SRCs (3.6-fold increase) in 1 × 10 6 uncultured, vehicle-treated and MB05032-treated cells, respectively. Another independent limiting-dilution analysis (LDA) showed a similar effect of MB05032 ( Supplementary  Fig. 10b,c and Supplementary Tables 8 and 9) .
Because early recovery of myeloid cells is important in CBtransplantation-based therapy, we also evaluated myeloid engraftment of GW9662-and MB05032-treated CB cells at 2 and 4 weeks after transplantation. Myeloid chimerism was significantly increased in both the PB and BM of recipients that were infused with GW9662-or MB05032-treated CB cells, as compared to that after infusion of vehicle-treated cells (Supplementary Fig. 10d-g ).
Treatment with MB05032 promoted glycolysis, glucose uptake and lactate production in CB CD34 + cells (Fig. 4i-k) . Similarly to the expansion of CB HSCs observed after PPAR-γ antagonism, expansion of CB HSCs by MB05032 treatment was suppressed by depletion of glucose or by administration of 2-DG (Fig. 4l,m) . This result is consistent with the concept that, by facilitating glycolysis, loss of FBP1 expression promotes ex vivo expansion of human CB HSPCs. Due to the established role of FBP1-mediated glycolysis in cancer cells, we checked the safety of CB HSPCs that had been expanded by antagonism of the PPAR-γ-FBP1 axis. In the course of our in vivo transplantation experiments, there were no significant changes in the survival rates between animals that were transplanted with control CB CD34 + cells and those that were transplanted with GW9662-or MB05032-treated cells (Supplementary Fig. 11a,b) . Also, we did not detect any effects of GW9662 or MB05032 treatment of CB HSCs on histone acetylation and methylation levels, including acetylation of histone H3 on Lys9 (acH3K9) or Lys14 (acH3K14), acetylation of histone H4 on Lys5 (acH4K5) or Lys16 (acH4K16), or trimethylation of histone H3 on Lys27 (tri-meH3K27) ( Supplementary  Fig. 11c-g ), suggesting that GW9662-or MB05032-treated cells are not epigenetically reprogrammed. Moreover, GW9662-or MB05032-treated CB CD34 + cells did not induce teratoma formation in vivo (Supplementary Fig. 12a,b) . Taken together, these data indicate that antagonism of PPAR-γ-FBP1 signaling does not induce malignant transformation of CB HSPCs. The mechanisms underlying self-renewal and expansion of human CB HSCs are poorly understood. Here we performed a compound screen using an ex vivo expansion assay and found that the PPAR-γ antagonist GW9662 promoted the expansion of functionally engrafting HSCs from a phenotypically defined population of HSCs (Lin − C D34 + CD38 − CD45RA − CD49f + CD90 + ) 17 in both primary and secondary transplantation assays. We also calculated the number of SRCs in uncultured and ex-vivo-expanded CD34 + cells by an LDA 1, 32 . As has been seen in numerous other studies, the number of SRCs is much lower than the number of phenotypic HSCs, consistent with the concept that not all phenotypically defined HSCs have the capability to engraft. Also, calculation of the number of SRCs is a relative quantification of the number of functional human HSCs, not an absolute quantification, as we cannot be sure that all potentially functional HSCs successfully engrafted the BM of recipient mice.
These results indicate that a PPAR-γ-FBP1 pathway functions to repress glycolysis and thereby restrict human CB HSC expansion. PPARs are members of the nuclear hormone receptor superfamily, a group of ligand-activated transcription factors involved in many physiological processes including differentiation, development, inflammation and metabolism [33] [34] [35] . Previous studies have identified certain nuclear receptors as key regulators of stemness and of the differentiation of embryonic stem cells and somatic stem cells 36 . Antagonism of the retinoic acid receptor (RAR) disrupts the reconstituting activity of mouse HSCs 37,38 but promotes the maintenance of human HSCs 39, 40 , suggesting that retinoic acid signaling has different roles in mouse and human HSC fate determination. Considering that GW9662 and two other compoundsStemRegenin1 (SR1) and UM171, which have been shown to expand human CB HSPCs, have no effect on expansion of mouse HSCs 10, 15 , it may be that the self-renewal of mouse and human HSCs are differentially regulated.
Although a PML-PPAR-δ-FAO pathway has been reported to control asymmetric cell division of mouse HSCs 29 , the function of PPAR signaling in human HSCs has not previously been described. Our findings demonstrate that antagonism of the PPAR-γ pathway drives expansion of human CB HSPCs by enhancing FBP1-repressed glycolysis and preventing differentiation. Use of either a PPAR-γ antagonist or a FBP1 inhibitor enhances long-term engraftment of self-renewing human CB HSCs, suggesting a new strategy to facilitate human CB HSC expansion by driving glucose metabolism.
MeTHOdS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
Isolation of mouse lineage-negative bone marrow cells and cell culture.
Mouse BM-lineage cell depletion was performed with the mouse lineage cell depletion kit according to the manufacturer's protocol (Miltenyi Biotec, Auburn, CA, USA). Lineage (Lin)-negative mouse BM cells were cultured in RPMI-1640 medium (Lonza, cat. no. 12-702Q) with 10% FBS (GE Healthcare, HyClone, cat. no. SH30071.03), 100 ng/mL mouse SCF (mSCF) (R&D Systems, cat. no. 455-MC-010), 100 ng/mL mouse TPO (mTPO) (R&D Systems, cat. no. 488-TO-005/CF) and 100 ng/mL mouse FL (mFtl3L) (BioLegend, cat. no. 550706).
Immunostaining and flow cytometry. Immunostaining and flow cytometry analysis were performed as previously described 18, 32 . Cells were collected by centrifugation at 300g for 10 min, washed twice with cold PBS and resuspended in 200 µL PBS. Cells were stained with antibodies conjugated to a fluorescent molecule at 4 °C for 30 min. Cells were washed with cold PBS, and the cell pellets were fixed with 1% formaldehyde. Samples were analyzed on an LSRII flow cytometer (BD Biosciences). For intracellular staining, after staining for cell surface molecules, cells were fixed and permeabilized using the Cell Permeabilization Kit (Thermo Fisher, Florence, KY, USA). Cells were washed with cold PBS and stained with primary antibodies at room temperature for 20 min. -1) (Biolegend, cat. no. 122513) , APC-conjugated anti-mouse CD117 (c-Kit) (Biolegend, cat. no. 105811), FITC-conjugated anti-mouse-CD48 (Biolegend, cat. no. 103404) and PerCP/Cy5.5-conjugated anti-mouse CD150 (Biolegend, cat. no. 115922). For phenotypic HSC quantification in ex vivo expansion assays, Lin − CD34 + CD38 − CD45RA − CD49f + CD90 + human CB cells are defined as phenotypic HSCs (pHSCs). By flow cytometry analysis, we determined the frequency of pHSCs in cultures of CB CD34 + cells. A total of 50,000 CD34 + cells were cultured; the total number of CD34 + cells were counted on days 4 and 7, and the frequency of pHSC was determined by flow cytometry at days 0, 4 and 7.
CFSE labeling assay. CB CD34 + cells were labeled with CellTrace CFSE dye to trace cell proliferation (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's instructions. CD34 + cells were incubated with 5 µM CFSE for 20 min at 37 °C, while being protected from light. Cells were washed with culture medium containing 1% BSA. Labeled cells were cultured for 24 h. CD34 + cells from a single CFSE peak were sorted using a FACSAria instrument (BD Biosciences). Sorted cells were cultured with expansion medium (RPMI-1640 medium with 10% FBS + SCF, TPO and FL) in the presence of vehicle or GW9662. Four days later, the CFSE intensity of CD34 + cells was analyzed by flow cytometry.
Annexin V staining. Vehicle-or GW9662-treated CD34 + cells were stained with an APC-conjugated human-CD34-specific monoclonal antibody (clone 581; BD Biosciences) for 30 min on ice. After washing, cells were stained with FITC-labeled Annexin V (BD Biosciences, cat. no. 556419) for 15 min at room temperature, and the cells were then washed and fixed. The percentage of apoptotic cells was determined by FACS.
Colony-forming unit (CFU) assay. Human CB CD34 + cells were plated in semi-solid methylcellulose culture medium in the presence of 30% FBS (FBS) (GE Healthcare, HyClone, cat. no. SH30071.03), 2 mM l-glutamine (Lonza, cat. no. 17-605E), 100 µM β-mercaptoethanol (Sigma, cat. no. M6250), 1 U/mL erythropoietin (EPO) (R&D Systems, cat. no. 287-TC-500), 50 ng/mL SCF (R&D Systems, cat. no. 7466-SC-010/CF), 10 ng/mL IL-3 (R&D Systems, cat. no. 203-IL-050/CF) and 10 ng/mL GM-CSF (R&D Systems, cat. no. 7954-GM-010) and were cultured in a 5% O 2 /5% CO 2 humidified incubator 32 . The number of colonies was scored with an inverted microscope 14 d after seeding.
In vivo transplantation. The progeny cells of 30,000 CD34 + CB cells that were treated with vehicle or GW9662 for 4 d were intravenously transplanted into sublethally irradiated primary NSG recipient mice (350 cGy; 137 Cs source, single dose). The percentage of human CD45 + cells in the PB was checked at 2 and 4 months after transplantation. Primary recipient mice were euthanized, and the percentage of human CD45 + , CD33 + , CD19 + and CD3 + cells in the BM was checked by immunostaining and flow cytometry. For second transplantation, 5 × 10 6 BM cells from primary recipients were intravenously transplanted into sublethally irradiated secondary NSG recipient mice. The percentage of human CD45 + CD33 + CD19 + cells in PB or BM was evaluated at 4 months after transplantation.
Limiting-dilution analysis. The frequency of human SCID repopulating cells (SRCs) was determined by an LDA, as previously reported 32 . Increasing doses of uncultured or of vehicle-, GW9662-or MB05032-treated CD34 + cells (500, 2,500 or 10,000 cells) were intravenously injected into sublethally irradiated NSG recipient mice (350 cGy; 137 Cs source, single dose). Three or 4 months after transplantation, the percentage of human CD45 + cell chimerism was analyzed by immunostaining and flow cytometry. For long-term engraftment assay, 5 × 10 6 BM cells from the primary recipients of the 10,000-cell group were intravenously transplanted into secondary recipient mice. Based on our immunostaining and flow cytometry analysis, we found that negative control samples sometimes showed 0.1~0.3% human CD45 + cells. To exclude the possibility of nonspecific staining, we defined samples with >1% human CD45 + cells as indicative of successful transplantation 32 . The HSC frequency was calculated using L-Calc software (Stem Cell Technologies Inc., Vancouver, BC, Canada) and plotted using ELDA software (http://bioinf.wehi.edu.au/software/elda/).
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Experimental design 
Data exclusions
Describe any data exclusions.
There is no data exclusions.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
The experimental findings were reliably reproduced through independent experiments.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
We used NSG mice of similar ages (6-8 weeks), and usually female mice as recipients. During the transplantation, mice were randomly placed into cages.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was done for animal studies.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
